OCGN – Ocugen, Inc.
Ocugen, Inc.OCGN
$0.95Name : Ocugen, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $322,341,248.00
EPSttm : -0.2
Ocugen, Inc.
$0.95
2.27%$0.022
OCGN — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
32.34
Margin Of Safety %
Put/Call OI Ratio
0.13
EPS Next Q Diff
-0.02
EPS Last/This Y
-0.01
EPS This/Next Y
-0.02
Price
0.95
Target Price
12.17
Analyst Recom
1
Performance Q
-32.14
Upside
-373.7%
Beta
1.93
Ticker: OCGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | OCGN | 0.9485 | 0.21 | 0.08 | 78452 |
| 2026-10-13 | OCGN | 0.8898 | 0.21 | 0.13 | 78382 |
| 2026-10-14 | OCGN | 0.8394 | 0.20 | 0.17 | 78050 |
| 2026-10-15 | OCGN | 0.8136 | 0.20 | 0.13 | 78718 |
| 2026-10-16 | OCGN | 0.7997 | 0.20 | 0.38 | 78898 |
| 2026-10-19 | OCGN | 0.7907 | 0.16 | 0.10 | 57355 |
| 2026-10-20 | OCGN | 0.8185 | 0.16 | 0.04 | 57769 |
| 2026-10-21 | OCGN | 0.8134 | 0.15 | 0.01 | 58345 |
| 2026-10-22 | OCGN | 0.8036 | 0.15 | 0.03 | 59351 |
| 2026-10-23 | OCGN | 0.7389 | 0.15 | 0.01 | 59504 |
| 2026-10-26 | OCGN | 0.7181 | 0.15 | 0.02 | 59634 |
| 2026-10-27 | OCGN | 0.7659 | 0.15 | 0.70 | 60194 |
| 2026-10-28 | OCGN | 0.7811 | 0.16 | 0.04 | 61212 |
| 2026-10-29 | OCGN | 0.7475 | 0.15 | 0.06 | 61300 |
| 2026-10-30 | OCGN | 0.7086 | 0.15 | 0.02 | 61524 |
| 2026-11-02 | OCGN | 0.7298 | 0.14 | 0.10 | 67562 |
| 2026-11-03 | OCGN | 0.7543 | 0.14 | 0.05 | 67829 |
| 2026-11-04 | OCGN | 0.8744 | 0.14 | 0.01 | 68132 |
| 2026-11-05 | OCGN | 0.805 | 0.13 | 0.15 | 70602 |
| 2026-11-06 | OCGN | 0.9271 | 0.13 | 0.02 | 70634 |
| 2026-11-09 | OCGN | 0.9734 | 0.13 | 0.17 | 73368 |
| 2026-11-10 | OCGN | 0.9446 | 0.13 | 0.04 | 73695 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | OCGN | 0.95 | 23.8 | - | -0.24 |
| 2026-10-13 | OCGN | 0.89 | 23.8 | - | -0.24 |
| 2026-10-14 | OCGN | 0.84 | 23.8 | - | -0.24 |
| 2026-10-15 | OCGN | 0.81 | 23.8 | - | -0.24 |
| 2026-10-16 | OCGN | 0.80 | 23.8 | - | -0.24 |
| 2026-10-19 | OCGN | 0.79 | 23.8 | - | -0.24 |
| 2026-10-20 | OCGN | 0.79 | 23.8 | - | -0.24 |
| 2026-10-21 | OCGN | 0.82 | 23.8 | - | -0.24 |
| 2026-10-22 | OCGN | 0.81 | 23.8 | - | -0.24 |
| 2026-10-23 | OCGN | 0.74 | 23.8 | - | -0.24 |
| 2026-10-26 | OCGN | 0.72 | 23.8 | - | -0.24 |
| 2026-10-27 | OCGN | 0.77 | 23.8 | - | -0.24 |
| 2026-10-28 | OCGN | 0.78 | 23.8 | - | -0.24 |
| 2026-10-29 | OCGN | 0.75 | 23.8 | - | -0.24 |
| 2026-10-30 | OCGN | 0.71 | 23.8 | - | -0.24 |
| 2026-11-02 | OCGN | 0.73 | 23.8 | - | -0.24 |
| 2026-11-03 | OCGN | 0.75 | 23.8 | - | -0.24 |
| 2026-11-04 | OCGN | 0.87 | 23.8 | - | -0.24 |
| 2026-11-05 | OCGN | 0.81 | 23.8 | - | -0.24 |
| 2026-11-06 | OCGN | 0.93 | 0.0 | - | -0.24 |
| 2026-11-09 | OCGN | 0.97 | 0.0 | - | -0.24 |
| 2026-11-10 | OCGN | 0.95 | 0.0 | - | -0.24 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | OCGN | -5.64 | 12.00 | 30.86 |
| 2026-10-13 | OCGN | -5.64 | 12.00 | 30.86 |
| 2026-10-14 | OCGN | -10.88 | 12.00 | 30.86 |
| 2026-10-15 | OCGN | -10.88 | 12.00 | 30.86 |
| 2026-10-16 | OCGN | -10.88 | 12.00 | 30.86 |
| 2026-10-19 | OCGN | -10.88 | 11.58 | 30.86 |
| 2026-10-20 | OCGN | -10.88 | 11.58 | 30.86 |
| 2026-10-21 | OCGN | -10.88 | 11.58 | 30.82 |
| 2026-10-22 | OCGN | -11.50 | 11.58 | 30.82 |
| 2026-10-23 | OCGN | -11.50 | 11.58 | 30.82 |
| 2026-10-26 | OCGN | -11.50 | 11.30 | 30.82 |
| 2026-10-27 | OCGN | -11.50 | 11.30 | 32.36 |
| 2026-10-28 | OCGN | -11.50 | 11.30 | 32.36 |
| 2026-10-29 | OCGN | -11.50 | 11.30 | 32.36 |
| 2026-10-30 | OCGN | -11.50 | 11.30 | 32.36 |
| 2026-11-02 | OCGN | -11.50 | 11.31 | 32.36 |
| 2026-11-03 | OCGN | -11.50 | 11.31 | 32.36 |
| 2026-11-05 | OCGN | -11.50 | 11.31 | 32.36 |
| 2026-11-06 | OCGN | -11.50 | 11.31 | 32.36 |
| 2026-11-09 | OCGN | -11.49 | 11.14 | 32.34 |
| 2026-11-10 | OCGN | -11.49 | 11.14 | 32.34 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.06
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
-0.08
Insider Transactions
-11.49
Institutional Transactions
11.14
Beta
1.93
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
13
Growth Score
26
Sentiment Score
54
Actual DrawDown %
89.9
Max Drawdown 5-Year %
-96
Target Price
12.17
P/E
Forward P/E
PEG
P/S
67.44
P/B
P/Free Cash Flow
EPS
-0.2
Average EPS Est. Cur. Y
-0.24
EPS Next Y. (Est.)
-0.25
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1367.61
Relative Volume
1.08
Return on Equity vs Sector %
343.4
Return on Equity vs Industry %
363.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.03
EBIT Estimation
◆
OCGN
Healthcare
$0.95
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
57
Range 1M
72.2%
Sup Dist
1.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
0%
EPS NY
-17.4%
52W%
12.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+1181.1% upside
Upside
+1181.1%
Quality
13
OCGN — P/E HistoricalBiotechnology
Ocugen, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 116
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
OCGN
Latest News
—
Caricamento notizie per OCGN…
stock quote shares OCGN – Ocugen, Inc. Stock Price stock today
news today OCGN – Ocugen, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCGN – Ocugen, Inc. yahoo finance google finance
stock history OCGN – Ocugen, Inc. invest stock market
stock prices OCGN premarket after hours
ticker OCGN fair value insiders trading